~~<i id='9CEDE1E553'><strike id='9CEDE1E553'><tt id='9CEDE1E553'><pre id='9CEDE1E553'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

author：fashion 2025-10-02 01:51:54 - browse：473

Judge's gavel — Legal experts unpacked the pharmaceutical industry's scattershot approach to challenging Medicare's new power to negotiate drug prices. Adobe

WASHINGTON — The pharmaceutical industry has been filing a lawsuit here, there, and pretty much everywhere.

Drugmakers lost a two-decade long lobbying fight in Congress last summer when Democrats gave Medicare more power to choose what it pays for prescription drugs. Now, they’re taking their battle to the courts.

Merck filed suit in the District of Columbia. Bristol Myers Squibb filed in New Jersey. The Chamber of Commerce filed in Ohio. PhRMA filed in Texas. And there’s no reason to believe the barrage of lawsuits will stop anytime soon.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： 4 missing after record

focus

explore

knowledge

Wikipedia

explore

AmedicalassistantataUniversityofWashingtonMedicineclinicpreparesatwo-shotdoseofEvusheldinJanuary2022

WSS

'Make People Better': The CRISPR babies story you probably don't know

How to protect coverage of PrEP

Where does female orgasm come from? Scientists think they know

The 10 drugs up first for Medicare price negotiation

Humana sues Biden admin over Medicare Advantage audit rule

Stem cell treatment guidelines are released by FDA

focus

focus

focus

How to save PrEP access — and even expand it

Men with early prostate cancer can safely opt out of treatment

Activists slam private health insurers over coverage restrictions

Sophia Smith scores twice for US in in 3

ChatGPT in medicine: STAT answers readers' burning questions

The (many) problems with a new study criticizing cancer screening

DIEP, the 'gold standard' of breast reconstruction, is under threat

ALS advocates say criticism of new drugs misses bigger picture

Bright Health sells Medicare Advantage business to Molina

Covid hospitalizations on the rise, Humana says

focus

FDA approves first blood sugar monitor without finger pricks

Men with early prostate cancer can safely opt out of treatment

How generative AI is inspiring dreams of a health data revolution

Crinetics acromegaly drug succeeds in late

Drone hits Crimean ammunition depot as strikes kill, wound civilians and journalists in Ukraine

How generative AI is inspiring dreams of a health data revolution

explore

knowledge

Wikipedia

explore